Novel Serum Biomarkers for Diagnosing MASLD in Adolescents: A Comparative Clinical Study

Manuscript Summaries

By NATHAN

Published on: 28th August, 2025

Background: The Need for Better MASLD Diagnostics in Youth

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disease in adolescents, largely driven by the rising prevalence of obesity. This condition encompasses a pathological spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advancing toward fibrosis and cirrhosis if left unchecked.
While alanine aminotransferase (ALT) remains the most widely used biomarker, it lacks specificity for disease severity and fibrosis progression. Consequently, clinicians require novel, non-invasive serum biomarkers that reliably distinguish MASLD from obesity alone and correlate with liver histopathology — particularly in pediatric populations where biopsy remains the gold standard but carries procedural risks.

Study Aim: Direct Comparison of Protein and microRNA Biomarkers

This cross-sectional pilot study evaluated six serum protein biomarkers and four microRNA (miRNA) candidates in adolescents with and without biopsy-proven MASLD. It aimed to:

  1. Compare multiple biomarkers side-by-side in pediatric MASLD.
  2. Identify those associated with histopathological severity, including fibrosis stage.
  3. Examine serum–liver relationships in miRNA expression and their mRNA targets.

Methods: Rigorous Design and Well-Matched Controls

Participant Cohorts

Adolescents aged 12–20 years were recruited into three groups:

  • Normal weight controls (NW) – BMI 5th–84th percentile.
  • Obesity controls (Ob) – BMI ≥95th percentile, no MASLD.
  • MASLD group – Obesity with biopsy-confirmed MASLD.

The groups were matched for age, sex, and ethnicity, with exclusion of type 2 diabetes and other secondary causes of steatosis. Importantly, obesity controls were carefully screened to rule out subclinical liver disease.

Assessments

  • Anthropometry and body composition via DXA.
  • Aerobic fitness and physical activity monitoring.
  • Fasting biochemical panel including lipids, NEFA, ALT, AST, and CRP.
  • Six serum proteins: full-length cytokeratin 18 (CK-18, M65), CK-18 fragments (M30), collagen IV (Col-IV), N-terminal propeptide of type III procollagen (PIIINP), YKL-40, and hyaluronic acid.
  • Four miRNAs: miR-122, miR-192, miR-130b, and miR-155.
  • Liver biopsy in MASLD group for histology, hepatic miRNA, and mRNA targets (AGPAT1, DGAT1, ATGL, SREBP-1c, ChREBP).

Key Findings: Biomarker Performance and Clinical Implications

  1. Serum CK-18 Outperforms ALT in MASLD Detection
  • Full-length CK-18 was 8.5× higher than NW controls and 8.3× higher than obesity controls.
  • AUROC for CK-18 (0.962) exceeded that of ALT (0.935), making it the strongest single predictor of MASLD in this adolescent cohort.
  • CK-18 fragments also showed significant elevation and correlation with fibrosis stage.
  1. miR-122 and miR-192: Equally Strong, Non-Enzymatic Indicators
  • Both miR-122 and miR-192 were markedly elevated in MASLD versus both control groups (miR-122 up to 11× higher than NW).
  • They demonstrated AUROC values (0.944 and 0.945) exceeding ALT, with positive correlations to fibrosis and trunk fat mass.
  • Notably, serum and liver miR-122 levels were inversely correlated supporting the hypothesis of increased hepatic export during disease progression.
  1. Other Biomarkers: Limited Diagnostic Advantage
  • Col-IV and YKL-40 were elevated compared to NW but did not outperform ALT.
  • PIIINP showed an association with fibrosis but lacked discrimination between MASLD and obesity alone.
  • Hyaluronic acid showed no group differences.
  1. miR-130b and miR-155: Pathophysiological Roles, Modest Clinical Utility
  • miR-155 was not significantly altered in MASLD serum but correlated with hepatic AGPAT1 and miR-122, suggesting a role in lipid metabolism and inflammation.
  • miR-130b was only slightly elevated and had modest correlations with injury markers, making it less promising as a serum diagnostic tool in adolescents.

Clinical Relevance: MASLD vs. Obesity Alone

A major strength of this study lies in differentiating MASLD biomarkers from obesity-related changes, a critical distinction in pediatric hepatology.
Although both obesity and MASLD groups had similar insulin resistance, ALT, AST, NEFA, triglycerides, CK-18, miR-122, and miR-192 were higher in MASLD, underscoring their disease-specific potential.

Limitations and Future Directions

  • Small cohort size and lack of a validation group.
  • Underrepresentation of advanced fibrosis cases, reflecting typical pediatric MASLD demographics.
  • A cross-sectional design prevents assessment of biomarker changes over time.
  • Dietary influences and variations in pubertal stage were not fully controlled.

Future research should focus on longitudinal validation in larger, ethnically diverse pediatric cohorts, integrating these biomarkers into non-invasive diagnostic panels for clinical practice.

Conclusion: Toward a New Pediatric MASLD Biomarker Panel

This study identifies serum CK-18, miR-122, and miR-192 as equal or superior to ALT for identifying MASLD in adolescents, with meaningful correlations to fibrosis.
For healthcare professionals managing adolescent obesity and liver health, these results provide an evidence-based rationale for further integrating novel protein and miRNA biomarkers into MASLD screening protocols alongside current clinical and imaging tools.

Key Clinical Takeaway:

In pediatric MASLD, CK-18, miR-122, and miR-192 show superior diagnostic accuracy to ALT, offering potential for earlier, non-invasive detection and differentiation from obesity alone.

Source/Read full paper: https://doi.org/10.1111/jcmm.70817


LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT

 

Share this post